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Objective: To determine the prevalence, level of severity of potential drug–drug in-
teractions (PDDIs) and the associated factors for PDDIs in hospitalized pediatric patients
of Gondar University Hospital.
Methods: A retrospective cross-sectional study was conducted for a period of 3 months
from March to May 2014 in pediatric wards of Gondar University Hospital. Systematic
random sampling technique was used to select charts from all pediatric patients' charts
with every 7th interval to get sample size of 384. Univariate and multivariate analysis
were performed to compute crude odds ratio and adjusted odds ratio respectively. Sta-
tistical signiﬁcance was set at P value < 0.05.
Results: A total of 176 (45.8%) patients had at least one PDDI. A total of 393 PDDIs,
which were comprised of 283 types of interacting combinations, were identiﬁed. Of the
total of 393 PDDIs, most were of moderate severity [201 (51%)] followed by minor [152
(39%)] and major severity [40 (10%)]. The most common interacting pairs of major
severity were gentamicin + furosemide (6), cotrimoxazole + methotrexate (4) and
phenytoin + artemether (4). The occurrence of PDDIs was signiﬁcantly associated with
age and polypharmacy.
Conclusions: The study showed that most of the interactions had moderate severity
followed by minor severity. Age and polypharmacy were found to show statistically
signiﬁcant association with the occurrence of PDDIs. Due to sensitive nature of pediatrics
population, close monitoring is recommended for the detection and management of
PDDIs to prevent its negative consequences.1. Introduction
Selecting a drug for a particular disease is one of the processes
for the quality of pharmacotherapy. The possibility of a druginﬂuencing the safety or efﬁcacy of another drug (a drug–drug
interaction) is vital for the optimal choice for pharmacotherapy [1].
Drug–drug interaction is an important factor for various adverse
consequences such as adverse drug events [1–5]. The incidence
of adverse drug event was high among pediatric patients
hospitalized in Jimma University Specialized Hospital,
Ethiopia. The incidences were found to be 9.2 per 100
admissions, 1.7 per 1000 medication doses, 9.4 per 1000
patient days and 2.8 per 100 medication orders [6].
The mechanism of drug interactions may be due to phar-
macokinetic, pharmacodynamics or clinical responses for drugs
administered together in which the combined effect is different
from the identiﬁed effects of individual drugs alone [7]. In terms
of severity, drug interactions may be major interactions which
may cause threat to life or lasting damages. ModerateThis is an open access article under the CC BY-
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not have a signiﬁcant effect on the therapy. Drug interactions
may have favorable or desirable, over and above undesirable
or harmful effects [8]. These interactions can augment or
lessen the effectiveness of each other or can also make new
side effects [9]. As various recent studies reported, rates of
potential drug–drug interactions (PDDIs) vary from
approximately 19.3% to 78% [10–13].
Polypharmacy is one of the common risk factors for PDDIs
which thereby cause adverse drug reactions and may lead to an
increased risk of hospitalization and higher health care costs
[14–19]. Although prescribing of more drugs for one patient
may be logical and necessary practice for patients
particularly those with co-morbidity, physicians should take
into account that PDDIs incidence approaches 40% for patients
taking 5 drugs, and exceeds 80% for patients taking 7 or more
medications [19]. In addition to polypharmacy, other risk
factors also exist and affect the incidence of PDDIs such as
age, acute medical condition, gender, prescriptions from
multiple physicians and drugs with narrow therapeutic range
[11,19,20].
Hospitalized pediatric patients face higher risk of drug-
induced problems due to wide-ranging of patient ages and
body-weights, limited physiologic reserve, medications dosing
errors and inaptitude to properly communicate with healthcare
workers [21]. In such situation, PDDIs are more likely to cause
adverse outcomes in pediatrics hospital patients, though most
of studies are limited to adult patients. Moreover, there have
not been published reports on studies that evaluate PDDIs
among pediatrics hospital patients in Ethiopia. Therefore, this
study was initiated to determine the prevalence, level of
severity of PDDIs and the associated factors for PDDIs in
hospitalized pediatrics patients of Gondar University Hospital
(GUH).
2. Materials and methods
2.1. Study area
The study was conducted in pediatrics ward of GUH, which
is one of the oldest and the pioneer teaching hospital located in
Amhara region, northwest part of Ethiopia. The hospital is
equipped with 550 beds to provide both inpatient and outpatient
services for at least 500000 population living in and around
Gondar.
2.2. Study design and period
A retrospective cross-sectional study was conducted for a
period of 3 months from March to May 2014 in pediatrics ward
of GUH, Ethiopia.
2.3. Inclusion and exclusion criteria
The source population was all patients visiting the Pediatrics
Department of GUH and the study population was all hospital-
ized pediatric patients during eight-month period. All pediatric
patients' chart containing order sheets with two or more drugs
and drugs prescribed at the day of admission were included inthe study. Pediatric charts containing order sheets with supple-
mentary diet only, pediatric charts containing order sheets with
IV ﬂuids and blood products only, pediatric charts containing
order sheets with medical supplies and equipments only and
pediatric charts containing only one drug were excluded from
the study.
2.4. Sample size determination
The sample size was determined using a formula for esti-
mation of single population proportion with the assumption of
95% conﬁdence level, margin of error of 5% and the prevalence
rate of PDDI was 50%.
n = (Za/2)2 × p (1 − p)/d2, n = (1.96)2 × 0.5 (1 − 0.5)/
(0.05)2 = 384
where, d = marginal error, p = proportion of sample population
with conﬁdence interval of 95%, Za/2 = the value under stan-
dard normal table for the given value of conﬁdence interval,
n = sample size.
Sample size of 384 patient medical records was taken.
2.5. Data collection procedures
Systematic random sampling technique was used to
select charts from those all pediatric patient charts with
every 7th interval to get sample size of 384, which were
documented from September 1, 2013 to April 30, 2014.
Patient charts selected with a 7:1 ratio from the two pedi-
atric wards. An eight-month review of pediatric patient's
charts was used as secondary source of data by using data
abstraction format. PDDIs were identiﬁed from patient
prescription at the time of admission. The occurrence and
severity of PDDI was analyzed using Micromedex
computer-based software. To ensure the quality data, pretest
was carried out to check the effectiveness of the data
collection instrument and data were collected after stan-
dardizing the data collection instruments.
2.6. Ethical clearance
The study protocol was performed according to the Helsinki
declaration and approved by Institutional Review Board of
University of Gondar, School of Pharmacy with the Ref. No.
SOP112/02/08 and conﬁdentiality was kept by using codes
rather than stating their names.
2.7. Data analysis
The collected data were checked by using Micromedex 2
software and analyzed by SPSS version 20. The processed
data were organized and presented by using frequency distri-
bution tables and hierarchies. Associated factors for the
occurrence of PDDIs were assessed using binary logistic
regression. Univariate and multivariate analyses were per-
formed to compute crude odds ratio (COR) and adjusted odds
Table 2
Frequencies of interacting drug combinations in pediatric wards.
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value < 0.05.Severity Interacting drug list Frequency
Major Gentamicin + furosemide 6
Phenytoin + artemether 4
Cotrimoxazole + methotrexate 4
Rifampicin + artemether 3
Captopril + allopurinol 3
Erythromycin + digoxin 3
Dexamethasone + artemether 2
Phenobarbital + artemether 2
Cimetidine + morphine 2
Enalapril + spironolactone 2
Moderate Lasix + potassium chloride 6
Metronidazole + dexamethasone 5
Spironolactone + lasix 4
Spironolactone + prednisolone 4
Phenytoin + digoxin 3
Ciproﬂoxacin + omeprazole 3
Chloramphenicol + ceftriaxone 33. Results
3.1. Patient demographic and clinical information
A total of 384 pediatric patients were enrolled in the
study. Among these, 219 (57.0%) were females. Pediatric
patients of various age groups were included with patients
younger than 1 month as the least prevalent age group of
2.3% followed by (1 month–2 years) age group of 21.1%.
Median age was 7.5 years (range 25 days–16 years). Number
of medications prescribed per patient were categorized as 2
(n = 144, 37.5%), 3 and 4 (n = 180, 46.9%), and 5 or more
(n = 60). Patients with co-morbidity were 212 (52.2%)
(Table 1).Table 1
General demographic and clinical data of the study subjects.
Characteristics Frequency Percentage
(%)
Age groups 0–1 month 9 2.3
1 month–2 years 81 21.1
2–6 years 82 21.4
6–12 years 101 26.3
12–18 years 111 28.9
Age median (range) 7.5 years (25 days–16 years)
Gender Male 219 57.0
Female 165 43.0
Co-morbidity Yes 212 52.2
No 172 44.8
PDDIs Yes 176 45.8
No 208 54.2
Prescribed medications per
patient
2 144 37.5
3 and 4 180 46.9
> 5 60 15.6
PDDIs per patient (mean) 1.023, range (0–4)
Major PDDIs per patient
(mean)
0.104, range (0–2)
Severity of PDDIs per
patients
Major 35/176 19.9
Moderate 113/176 64.2
Minor 107/176 60.8
Prednisolone + lasix 3
Phenytoin + phenobarbital 3
Metronidazole + cotrimoxazole 3
Salbutamol + gentamicin 2
Itraconazole + gentamicin 2
Allopurinol + cyclophosphamide 2
Doxycycline + ceftriaxone 2
Minor Nifedipine + prednisolone 4
Cimetidine + ciproﬂoxacin 4
Ceftriaxone + lasix 2
Metronidazole + diclofenac 2
Mechanisms of PDDIs (%)
PK (50%) PD (46%) Unkown (4%)
Excretion (6%)Metabolism (34%)Distribution 
(3.6%)
Absorbtion 
(6.4%)
Figure 1. Distribution of PDDIs based on their mechanism in pediatric
wards of Gondar University Hospital, Gondar, Ethiopia, May 2014.
PK: Pharmacokinetic; PD: Pharmacodynamic.3.2. Prevalence PDDIs
Of the total of 384 pediatric patients, 176 (45.8%) patients
had at least one PDDI regardless of type of severity (Table 1). Of
these patients having at least one PDDI, based on the frequency
of severity of PDDIs per patient, 64.2% (113/176) patients had
at least one moderate PDDI followed by minor PDDI occurring
in 60.8% (107/176) of patients (Table 1).
A total of 393 PDDIs were identiﬁed. Of these, most were
moderate severity [201 (51%)] followed by minor [152 (39%)]
and major severity [40 (10%)]. In this study, 283 types of inter-
acting drug combinations were identiﬁed. Frequencies of some
widespread interacting drug combinations were listed (Table 2).
Based on their mechanism of the total of 393 PDDIs iden-
tiﬁed, 50% (197/393) of PDDIs were pharmacokinetic with the
highest frequency of metabolism subtype (34%) (Figure 1).3.3. Association with predicting factors
On univariate and multivariate analysis (Table 3), COR
and AOR revealed that gender and co-morbidity did not show
signiﬁcant difference on the presence of PDDIs per patient.
However, the occurrence of PDDIs was signiﬁcantly associ-
ated with age and polypharmacy. This implied that PDDIs
were occurring more frequently in age group of 2–6 years
than any other age group of pediatric population
[AOR = 6.450; 95% conﬁdence interval (CI) (1.271–34.353)].
There was also a positive association between the number of
medications prescribed and the likelihood of PDDIs occur-
rence. When three or four medications [AOR = 2.220; 95%
CI (1.128–5.387)] and ﬁve or more medications
[AOR = 7.034; 95% CI (2.130–11.089)] were prescribed,
PDDIs were occurring more frequently than those patients
with two medications prescribed.
Table 3
Predicting factors of PDDIs in pediatric wards.
Variables PDDI P value OR (95% CI)
Present Absent COR AOR
Age (years) 0.001
0–1 month 2 7 – 1.00 1.00
1 month–2 years 37 44 0.066 4.121 (0.670–1.500) 4.655 (0.904–3.979)
2–6 years 39 43 0.029* 1.251 (1.070–2.560)* 6.450 (1.271–34.353)*
6–12 years 46 55 0.494 1.265 (0.120–1.570) 1.765 (0.346–2.006)
12–18 years 52 59 0.209 1.905 (0.450–7.120) 2.886 (0.552–1.090)
Gender 0.210
Male 98 121 – 1.00 1.00
Female 78 87 0.288 0.760 (0.210–1.560) 0.771 (0.478–1.246)
Co-morbidity 0.590
Present 73 139 – 1.00 1.00
Absent 103 69 0.771 0.387 (0.120–1.710) 0.926 (0.554–1.549)
Polypharmacy 0.001
2 33 111 – 1.00 1.00
3 and 4 101 79 0.001 1.340 (0.670–1.420) 2.220 (1.128–5.387)*
 5 42 18 0.001 4.650 (0.320–0.810)* 7.034 (2.130–11.089)*
*: Statistically signiﬁcant at P < 0.05.
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This study assessed the occurrence of PDDIs in pediatric
population. The prevalence and nature of PDDIs have been
reported in 384 pediatric patients. This study revealed that the
overall prevalence of at least one PDDI per patient was 45.8%
(176/384). It was comparable to Feinstein et al., which re-
ported that hospitalized pediatric patients exposed to a PDDI
were 49% [22]. Of 176 patients having at least one PDDI,
major interactions were found in 19.9% (n = 35) of pediatric
patients in this study. These ﬁndings were higher in
comparison to Ismail et al. in which overall interaction was
25% and major interaction was 10.7% (n = 43) [23]. But they
were less than the results of Feinstein et al., which found
exposure to the major interaction of PDDIs in 41% of
pediatric patients [22]. All PDDIs were not equally
detrimental, though, recognition of severity of each PDDIs
was central to assess clinical importance and appropriate
management [24,25].
As the list of interacting drug combinations, particularly
prevailing major and moderate interactions, are useful for health
care professionals to monitor patient proﬁles for PDDIs, this
study has also identiﬁed a total of 393 PDDIs.
Most interacting drug combinations were moderate severity
201 (51%) followed by minor 152 (39%) and major severity 40
(10%). In this study, most of the major severity PDDIs were
observed with gentamicin and furosemide (6 combinations)
which can potentially end up with life threatening of ototoxicity
and nephrotoxicity, though it is not common in children [26,27].
Similarly, cotrimoxazole and methotrexate (4 combinations)
have a higher risk of toxicity such as cytopenia, mucositis,
hepatotoxicity and gastrointestinal symptoms by increasing
toxicity of methotrexate by plasma protein binding
competition [28,29]. Co-administration of artemether with
phenytoin (4 combinations) leads to the loss of antimalarial ef-
ﬁcacy as phenytoin causes strong induction of CYP3A4 result-
ing in decrease of artemether concentration. This ﬁnding is
different from other studies, such as fentanyl + morphine
(13.2%) in Feinstein et al. [22], rifampin + pyrazinamide (14
cases), and phenobarbital + diazepam (14 cases) in Ismailet al. [23], whereas digoxin + furosemide (20.14%) in Yeh
et al. were identiﬁed as the most common major interactions [30].
Precautions need to be taken while prescribing such medi-
cations for pediatric patients. It is also important to monitor all
the possible and major PDDIs before prescribing to the patients
so as to minimize the potential consequences and manage them
accordingly.
The other result of this study showed that age group has
statistically signiﬁcant association with PDDIs which were
occurring more frequently in 2–6 years age group than any other
age group of pediatric [AOR = 6.450; 95% CI (1.271–34.353);
P < 0.029]. Assessment of the relationship between number of
medications prescribed and PDDIs indicated that polypharmacy
increases the likelihood of PDDIs occurrence. Bjerrum et al. also
described that polypharmacy has been shown to be associated
with PDDIs [31]. Polypharmacy could be very detrimental in
children because of their physiological eccentricity [32].
This study has some limitations. We could not ascertain with
any accurate completeness or reliability of the information ob-
tained as the study design was retrospective. As such, it was
possible that we could have under- or over-reported the PDDIs.
As some drugs were prescribed to be taken as required, we could
not accurately determine whether these drugs were actually
taken with others, which is difﬁcult to make the assessment of
drug–drug interaction. The ﬁndings of this study may not be
generalized as it is a single center study.
As the study showed most of the interactions had moderate
severity followed by minor severity. Age and polypharmacy
were risk factors for the occurrence of PDDIs. Therefore,
identifying and preventing potentially harmful PDDIs is a crit-
ical component of a pharmacist's mission and the clinical
pharmacist must remain vigilant in their monitoring of PDDIs
and make appropriate dosage or therapy adjustments. Due to
sensitive nature of pediatric population, close monitoring is
recommended for detection and management of PDDIs to pre-
vent its negative consequences.
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